CorMedix Inc.

NasdaqGM CRMD

CorMedix Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

CorMedix Inc. Net Cash Used Provided By Financing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • CorMedix Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 11.85 M, a -79.23% change year over year.
  • CorMedix Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 57.08 M, a 132.30% change year over year.
  • CorMedix Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 24.57 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
NasdaqGM: CRMD

CorMedix Inc.

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Similar companies

PGEN

Precigen, Inc.

USD 1.70

6.25%

ETON

Eton Pharmaceuticals, Inc.

USD 17.70

1.90%

NVCT

Nuvectis Pharma, Inc.

USD 6.67

-7.87%

CELC

Celcuity Inc.

USD 12.25

-2.70%

NUVB

Nuvation Bio Inc.

USD 2.38

-1.24%

ELDN

Eledon Pharmaceuticals, Inc.

USD 4.70

-1.05%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.40

-4.76%

TARS

Tarsus Pharmaceuticals, Inc.

USD 52.95

-0.69%

SGMO

Sangamo Therapeutics, Inc.

USD 1.15

-9.45%

GOSS

Gossamer Bio, Inc.

NA

NA

ELVN

Enliven Therapeutics, Inc.

USD 22.00

-2.09%

TVTX

Travere Therapeutics, Inc.

USD 21.75

-0.50%

ALDX

Aldeyra Therapeutics, Inc.

USD 5.93

-1.17%

REPL

Replimune Group, Inc.

USD 13.94

-0.85%

INBX

Inhibrx Biosciences, Inc.

USD 12.60

-2.70%

StockViz Staff

February 9, 2025

Any question? Send us an email